Clinical trials: Lipemia
Hyperlipidemia, Hypercholesterolemia
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin.
- Trial name
- NCT00203476
- Testing
- Niacin, Colestipol, Ezetimibe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tuscaloosa Research & Education Advancement Corporation
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Hypercholesterolemia
The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease
Some studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate…
- Trial name
- PIT-ROAD (NCT00548145)
- Testing
- Pitavastatin, cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Osaka University
Hypercholesterolemia
Open Label Study of Long Term Evaluation Against LDL-C Trial
The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.
- Trial name
- OSLER (NCT01439880)
- Testing
- Evolocumab, Standard of care
- Where
- 187 sites in United States, Australia and 16 more
- Volunteers
- 1,324 people
- Sponsor
- Amgen
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
A multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus atorvastatin in elderly patients with high cholesterol at high or moderately high risk for coronary heart disease.
- Trial name
- NCT00535405
- Testing
- Atorvastatin 10 mg, Ezetimibe 10 mg/simvastatin 20 mg, Atorvastatin 20 mg
- Volunteers
- 1,289 people
- Sponsor
- Organon and Co
Type II Hyperlipidemia
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C) in people with abnormal…
- Trial name
- NCT01388816
- Where
- 12 sites in Italy, Poland and 1 more
- Volunteers
- 176 people
- Sponsor
- Dr. Reddy's Laboratories Limited
HIV Infections, Hyperlipidemia
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Treatment of HIV with combination antiretroviral regimens frequently results in the suppression of HIV viral load, significant immune recovery, and delayed disease progression.
- Trial name
- NCT00663234
- Testing
- Atorvastatin
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Hyperlipidemia
Acute Microvascular Changes With LDL Apheresis
Severe hypercholesterolemia produced by conditions such as heterozygous familial hypercholesterolemia is associated with multiple complications including premature atherosclerotic disease.
- Trial name
- NCT02388633
- Testing
- Plasmapharesis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oregon Health and Science University
Dyslipidemia
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.
- Trial name
- EBBINGHAUS (NCT02207634)
- Testing
- Evolocumab, Background Statin Therapy
- Where
- 416 sites in United States, Australia and 28 more
- Volunteers
- 1,974 people
- Sponsor
- Amgen
Hyperlipidemia, HIV
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
The main goal of this study is to determine how taking efavirenz affects the levels of pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir with ritonavir affects the levels of pitavastatin…
- Trial name
- NCT01695954
- Testing
- Pitavastatin, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Hyperlipidemia
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from…
- Trial name
- LAPLACE-2 (NCT01763866)
- Testing
- Evolocumab, Ezetimibe, Atorvastatin
- Where
- 244 sites in United States, Australia and 19 more
- Volunteers
- 2,067 people
- Sponsor
- Amgen
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Coronary Heart Disease
Phytosterols, Ezetimibe, and Cholesterol Metabolism
Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear to have different mechanisms of action.
- Trial name
- Phyteaux-III (NCT00863265)
- Testing
- Ezetimibe, Phytosterols + ezetimibe
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Children with type1 diabetes (T1DM) have increased risk for cardiovascular disease (CVD) due to chronic increase in the blood sugars and inflammation.
- Trial name
- NCT01236365
- Testing
- Atorvastatin
- Where
- 5 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Nemours Children's Clinic
Familial Hypercholesterolemia
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
This was a long term follow on study to assess the continued long term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia.
- Trial name
- NCT00943306
- Testing
- lomitapide
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 19 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Hypercholesterolemia, Coronary Heart Disease
Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis
The purpose of the study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in treating severely hypercholesterolemic patients who are on a maximally tolerated lipid-lowering regimen and who are not on…
- Trial name
- NCT00794664
- Testing
- Mipomersen
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 58 people
- Sponsor
- Kastle Therapeutics, LLC
Hyperlipidemia, Diabetes
Tele-Pharmacy Intervention to Improve Treatment Adherence
The purpose of this cluster randomized controlled trial is to evaluate whether a novel tele-pharmacist-based intervention for patients with hyperlipidemia, hypertension, and diabetes improves medication adherence, disease…
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- STIC2IT (NCT02512276)
- Testing
- Telepharmacist intervention
- Where
- United States
- Volunteers
- 4,078 people
- Sponsor
- Brigham and Women's Hospital
Hypercholesterolemia
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
- Trial name
- NCT03847974
- Testing
- LIB003
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- LIB Therapeutics LLC
HIV, Hypercholesterolaemia
Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
To compare the effect of rosuvastatin to protease inhibitor switching on fasting total cholesterol over 12 weeks.
- Trial name
- SOS (NCT01935674)
- Testing
- Switch ritonavir-boosted PI, Continue Ritonavir-boosted PI+Rosuvastatin
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Juan A. Arnaiz